Outlook Therapeutics
OTLK
68 hedge funds and large institutions have $44.8M invested in Outlook Therapeutics in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 28 increasing their positions, 10 reducing their positions, and 7 closing their positions.
1,854% more call options, than puts
Call options by funds: $1.64M | Put options by funds: $84K
180% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 10
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
5% more funds holding
Funds holding: 65 → 68 (+3)
0.86% less ownership
Funds ownership: 36.29% → 35.43% (-0.86%)
6% less capital inflows, than outflows
Capital inflows: $9.06M | Capital outflows: $9.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.79M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.25M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$826K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$669K |
| 5 |
ACM
Altium Capital Management
New York
|
+$291K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Great Point Partners
Greenwich,
Connecticut
|
-$2.99M |
| 2 |
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$1.82M |
| 3 |
Caligan Partners
New York
|
-$1.33M |
| 4 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.16M |
| 5 |
Boothbay Fund Management
New York
|
-$663K |
OTLK Hedge Fund Activity: Q3 2024 in Review
68 of the 6,991 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q3 2024, worth a combined $44.8M — down 29% from $62.7M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new OTLK positions and 7 closed out — a net gain of 4 holders — while 28 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $2.79M. The largest seller was Great Point Partners, cutting an estimated $2.99M.
- 68 institutional investors held Outlook Therapeutics (OTLK) as of Q3 2024, up from 65 in Q2 2024.
- Funds reported $44.8M of Outlook Therapeutics stock for Q3 2024, down 29% quarter-over-quarter.
- 11 funds opened new Outlook Therapeutics positions in Q3 2024 and 7 closed out, a net change of +4 holders.
- The largest Outlook Therapeutics buyer in Q3 2024 was BlackRock, an estimated $2.79M added.
- The largest Outlook Therapeutics seller in Q3 2024 was Great Point Partners, an estimated $2.99M sold.
Based on aggregated 13F filings for Q3 2024.